What is survodutide, and how does the glucagon/GLP-1 dual agonist compare?

The short answer

Survodutide (BI 456906) is an investigational glucagon-receptor/GLP-1-receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. In Phase 2 trials it drove up to roughly 19% body-weight loss at 46 weeks and resolved liver disease (MASH) in up to 62% of patients — strong results that put it among the leading next-generation obesity drugs. It is not yet approved; Phase 3 trials are underway.

Evidence tier: Tier 1 for the Phase 2 trial results; Tier 2 for cross-trial comparisons. Educational content, not medical advice.

The key points:

• Dual mechanism: glucagon receptor + GLP-1 receptor (not GLP-1/GIP like tirzepatide)
• Phase 2 weight loss: up to ~18.7% on-treatment at 4.8 mg over 46 weeks
• Standout for the liver: up to 62% MASH resolution — the glucagon arm helps here
• Still investigational — not approved; Phase 3 (SYNCHRONIZE) ongoing

For the full drug-class context, see the GLP-1 complete guide.

What is survodutide?

Evidence tier: 2 — established pharmacology.

Survodutide, also known by its development code BI 456906, is a once-weekly injectable peptide that activates two receptors at once: the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). It's being developed jointly by Boehringer Ingelheim and Zealand Pharma for obesity and for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). That dual-agonist design places it in the same broad "next-generation" wave as tirzepatide and retatrutide, but with a distinct receptor combination — and that combination is the whole point.

The GLP-1 arm does what GLP-1 drugs are known for: it reduces appetite and food intake and improves glycemic control. The glucagon arm is what sets survodutide apart. Glucagon-receptor activation increases energy expenditure and, importantly, acts directly on the liver to mobilize and reduce hepatic fat. So instead of relying on appetite suppression alone, survodutide pairs eating less with burning more and targeting liver fat directly. That's why it has shown particular promise in liver disease, not just weight — a profile we map against the other dual and triple agonists in our next-gen multi-agonists overview.

How much weight does survodutide cause people to lose?

Evidence tier: 1 — Phase 2 randomized trial.

The headline obesity data come from a Phase 2, randomized, double-blind, placebo-controlled, dose-finding trial in adults with obesity (without diabetes), published in The Lancet Diabetes & Endocrinology (le Roux et al. 2024). At the top 4.8 mg dose over 46 weeks, mean body-weight reduction reached about −14.9% on the full analysis and −18.7% on-treatment, versus roughly −2 to −3% with placebo. Up to 40% of people at the highest doses lost at least 20% of their body weight — a threshold that puts survodutide in genuinely competitive territory with the strongest agents in development.

An important caveat sits inside those numbers: the trial used a slow dose escalation (over 5–9 weeks), and the gap between the "planned" and "on-treatment" figures reflects that some participants didn't reach or stay on the top dose, often due to side effects. So the ~19% figure represents people who tolerated and stayed on 4.8 mg — a realistic best case, not a guaranteed average. Separately, a 16-week Phase 2 trial in people with type 2 diabetes found survodutide produced greater weight loss than semaglutide 1.0 mg, though that's a shorter, lower-comparator-dose study and shouldn't be over-read. The honest summary: the Phase 2 efficacy is strong, but it's Phase 2, and Phase 3 will tell us how it holds up at scale.

Why is survodutide a big deal for liver disease (MASH)?

Evidence tier: 1 — Phase 2 randomized trial.

This is where survodutide's glucagon arm earns its keep. In a 48-week Phase 2 trial in adults with biopsy-confirmed MASH and fibrosis (stages F1–F3), published in the New England Journal of Medicine (Sanyal et al. 2024), survodutide achieved MASH resolution without worsening of fibrosis in roughly 47–62% of patients depending on dose — about 62% at the 4.8 mg dose — versus around 14% on placebo. That's a large effect in a condition with few approved therapies, and it's a meaningful chunk of why survodutide is being watched so closely.

The mechanistic logic is clean: MASH is fundamentally about excess liver fat and inflammation, and glucagon-receptor activation reduces hepatic fat directly, on top of the weight loss the GLP-1 arm helps drive. Drugs that hit only GLP-1 help the liver mostly via weight loss; survodutide adds a direct hepatic lever. It's now in a dedicated Phase 3 MASH program. As with the obesity data, this is Phase 2 — encouraging and biologically coherent, but not yet the confirmatory, regulator-grade evidence that approval requires.

Why does this matter beyond the liver-disease population? MASH is closely tied to obesity, type 2 diabetes, and cardiovascular risk, so a drug that simultaneously drives substantial weight loss and reverses liver pathology addresses several overlapping problems at once. That's the strategic appeal of the glucagon/GLP-1 combination, and it's why both the obesity and MASH programs are being pursued in parallel rather than as separate bets. If the Phase 3 data hold, survodutide could land as a genuinely dual-purpose metabolic drug — but "if the data hold" is doing real work in that sentence, and the history of MASH drug development is littered with Phase 2 successes that didn't replicate.

How does survodutide compare to Ozempic, Mounjaro, and retatrutide?

Evidence tier: 2 — cross-trial comparison, not head-to-head.

Mechanistically, the field now has several receptor combinations. Semaglutide (Ozempic/Wegovy) is GLP-1 only. Tirzepatide (Mounjaro/Zepbound) is GLP-1 + GIP. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Survodutide is GLP-1 + glucagon — sharing the glucagon component with retatrutide but without the GIP arm. The practical implication is that survodutide and retatrutide both bring the glucagon-driven energy-expenditure and liver-fat benefits, while tirzepatide leans on GIP instead.

A crucial caveat: these comparisons are cross-trial, not head-to-head. Different trials enroll different populations, use different durations and dosing, and report different endpoints, so comparing a ~19% figure here to a number from a separate tirzepatide or retatrutide trial is suggestive, not definitive. What's fair to say is that survodutide's Phase 2 weight loss is in the competitive range of the leading next-gen agents, and its MASH data are a genuine differentiator. For the appetite/side-effect mechanics that apply across this whole class, see managing GLP-1 side effects, and for where retatrutide sits, the retatrutide overview.

What are the side effects and current status?

Evidence tier: 1–2 — trial safety data plus regulatory status.

Survodutide's side-effect profile looks like the class: predominantly gastrointestinal — nausea, vomiting, diarrhea — and dose-related, which is exactly why the trials used a slow multi-week escalation to improve tolerability. The glucagon component can also modestly raise heart rate, a known feature of glucagon-receptor activation that Phase 3 monitoring will characterize further. As with all incretin drugs, tolerability and the ability to reach the higher (more effective) doses vary a lot between individuals.

On status, the key fact is that survodutide is investigational and not approved anywhere for obesity or MASH as of 2026. It's advancing through Phase 3 — the SYNCHRONIZE program for obesity (including a cardiovascular outcomes trial) and a Phase 3 MASH program — with trials registered publicly (ClinicalTrials.gov NCT04667377). That means you can't get it by prescription yet, and anything sold online as "survodutide" is gray-market and unverified — with all the authenticity and purity risks covered in spotting counterfeit peptides. The honest position is to treat survodutide as a highly promising drug to watch, not a currently available option.

Limitations

This is educational content, not medical advice.

• All efficacy data are Phase 2 — promising, but not confirmatory; Phase 3 is ongoing.
• Cross-trial comparisons aren't head-to-head — don't over-read survodutide vs tirzepatide/retatrutide numbers.
• Top-dose results reflect people who tolerated the top dose — real-world averages may be lower.
• Not approved anywhere — it's investigational; online "survodutide" is gray-market and unverified.
• Glucagon activation adds considerations (e.g. heart rate) still being characterized.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Survodutide (BI 456906) is one of the most promising next-generation metabolic drugs in development: a glucagon/GLP-1 dual agonist that delivered up to roughly 19% weight loss and up to ~62% MASH resolution in Phase 2, with the glucagon arm adding energy expenditure and direct liver-fat benefits that pure GLP-1 drugs don't have. It's still investigational — not approved, with Phase 3 trials underway — and the strongest figures reflect patients who reached and tolerated the top dose. It belongs on the watch list of anyone tracking obesity and liver-disease treatment, but it's not a drug you can or should be sourcing today.

Related on this site

• GLP-1 complete guide
• Next-gen multi-agonists overview
• Retatrutide overview
• Managing GLP-1 side effects
• Spotting counterfeit peptides & fake Ozempic
• Our evidence-tier framework

References

• le Roux CW, et al. 2024. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 12(3):162–173. doi:10.1016/S2213-8587(23)00356-X — Phase 2 obesity efficacy.
• Sanyal AJ, et al. 2024. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. doi:10.1056/NEJMoa2401755 — Phase 2 MASH resolution data.
• A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight. ClinicalTrials.gov NCT04667377 — trial registration and dosing.